Biolab & Co. and Sandoz Announce the Launch of Owozy (semaglutide) in the Brazilian Market
- The partnership combines Biolab & Co.'s national presence with Sandoz's global expertise to expand access to the medication and support its distribution in the country
- The goal is to place physicians at the center of the expansion strategy for GLP-1 medications, prioritizing responsible prescribing and access to innovation
São Paulo, August 19, 2026 – The launch of Owozy (semaglutide) in the Brazilian market is supported by a partnership that combines Biolab & Co.’s national presence with Sandoz’s global expertise. The medication remains stable for up to 42 days at temperatures up to 30°C, a feature that allows for greater flexibility in storage during the period of use.
Under the agreement, announced on Wednesday (19), Biolab Farmacêutica will be responsible for the medical promotion and marketing strategy for the drug, while Sandoz will be responsible for supplying the product. The partnership aims to make access to type 2 diabetes treatment more widely available and to raise awareness about the care and treatment of the disease. The move solidifies Biolab’s leadership in the cardiometabolic health segment.
The drug is expected to hit the market in the fourth quarter of 2026, backed by a strong promotional campaign targeting the medical community.
“Owozy’s entry into the Brazilian market represents an important opportunity to expand access to a high-quality treatment option for type 2 diabetes. ”Together with Biolab & Co., we are reinforcing our commitment to connecting more patients with reliable and affordable medications through partnerships that combine innovation, market knowledge, and local execution capabilities,", says Isabella Wanderley, president of Sandoz Brazil.
Owozy is the result of a global development platform led by Adalvo, with Ávita Care serving as the local regulatory representative during the approval process with Anvisa. The drug’s development was guided by rigorous regulatory requirements and by standards of quality, safety, and efficacy consistent with the level of confidence expected of an approved therapeutic option for the treatment of type 2 diabetes.
"GLP-1 medications are currently experiencing significant growth, and our role, as a leader in cardiology, is to ensure that innovation reaches patients responsibly and under medical guidance. ”The partnership with Sandoz to market Owozy reinforces our strong track record of supporting the medical community across various specialties, leveraging the strength of our sales force to expand safe access to this therapy in Brazil.”, says Fabio Amorosino, president of Biolab & Co.
Biolab Farmacêutica is part of Biolab & Co., a Brazilian pharmaceutical group that comprises six brands and has a portfolio of more than 900 products in the human health, veterinary health, and animal nutrition segments.
ABOUT THE MEDICATION
Owozy will be available in Brazil in Pre-filled delivery system (multi-dose and disposable pens), designed to make it easier for patients and healthcare professionals to manage type 2 diabetes. The product must be stored according to the instructions in the package insert. When refrigerated, the pen can be stored for up to 24 months, and after removal from the refrigerator, it can remain at room temperature for up to 42 days.¹
The approved presentations include:
- Semaglutide 1.34 mg/mL Injectable Solution, in an application form filled out with 1.5 mL, accompanied by 1 pen and 6 needles
- Semaglutide 1.34 mg/mL Injectable Solution, in an application form filled out with 3.0 mL, accompanied by 1 pen and 4 needles
This medication is indicated for weekly administration, as directed by a doctor.
The presentations adhere to technical criteria and international development standards, with a focus on consistency of treatment, safety, and suitability for the needs of patients with type 2 diabetes.
REFERENCES
- Official Gazette of the Union. Resolution-Re No. 2.942/2026. Available at: RESOLUTION-RE No. 2,942, OF JULY 28, 2026 - RESOLUTION-RE No. 2,942, OF JULY 28, 2026 - DOU - National Press. Accessed on: July 29, 2026.
About Biolab&Co
Biolab & Co. is a brand that brings together science, innovation, and health, operating in the fields of human health, veterinary medicine, and animal nutrition. Driven by knowledge and collaboration, the company’s mission is to develop and provide therapeutic solutions that have a positive impact on society, always guided by ethics, purpose, and integrity.
The group comprises six brands and a portfolio of more than 900 products. Its structure consists of the following business units: Biolab Farmacêutica, Biolab Genéricos, Avert Saúde Humana, Avert Biolab Saúde Animal, Exzell Pharma, and Pet Nutrition.
With the vision of becoming the leading Brazilian pharmaceutical group in its markets, Biolab & Co. operates three manufacturing facilities in the state of São Paulo and one in Minas Gerais, in addition to two Research, Development, and Innovation (R&D&I) centers. The group is also expanding its reach through its operations in Canada, where it markets products and maintains its own R&D&I center—the only one outside Brazil operated by a Brazilian pharmaceutical company. The result of this investment is more than 50 international partnerships and a track record of over 400 patent applications, reflecting a culture of continuous evolution and a focus on what matters most, delivered with excellence. Currently, more than 50% of its revenue comes from innovative and exclusive products.